Severe airflow limitation in two patients with systemic lupus erythematosus: Effect of inhalation of anticholinergics

Modern Rheumatology

Volumn 18, Issue 1, 2008, Pages 52-56

  Kawahata, Kimito ^a   Yamaguchi, Masao ^a   Kanda, Hiroko ^a   Komiya, Akiko ^a   Tanaka, Ryoichi ^a   Dohi, Makoto ^a   Misaki, Yoshikata ^a   Yamamoto, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Airflow limitation; Anticholinergics; Bronchiolitis obliterans (BO); Obstructive ventilatory defect; Systemic lupus erythematosus (SLE)

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTROPIUM BROMIDE; OXITROPIUM BROMIDE; TIOTROPIUM BROMIDE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CASE REPORT; CLINICAL FEATURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TOTAL LUNG CAPACITY;

ADMINISTRATION, INHALATION; ADULT; BRONCHIOLITIS OBLITERANS; CHOLINERGIC ANTAGONISTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED;

EID: 39149090988     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-007-0002-3     Document Type: Article

References (13)

1. Orens JB, Martinez FJ, Lynch JP 3rd. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 1994;20:159-93.
2. D'Cruz, D, Khamashta MA, Hughes G. Pulmonary manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Duboi's lupus erythematosus. 7th ed. Lippincott Williams & Wilkins; 2007. p. 678-99.
3. Costello RW, Fryer AD. Cholinergic mechanisms in asthma. In: Barnes PJ, Grunstein MM, Leff AR, Woolcock AJ, editors. Asthma. Lippincott-Raven Publishers; 1997. pp. 965-84.
4. Kinney WW, Angelillo VA. Bronchiolitis in systemic lupus erythematosus. Chest. 1982;82:646-9.
5. Katzenstein AL, Myers JL, Prophet WD, Corley LS 3rd, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986;10:373-81.
6. Godeau B, Cormier C, Menkes CJ. Bronchiolitis obliterans in systemic lupus erythematosus: Beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis. 1991;50:956-8.
7. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007-18.
8. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med. 2002;166:440-4.
9. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: A systematic review of recent publications. J Heart Lung Transplant. 2002;21:271-81.
10. Weber F, Prior C, Kowald E, Schmuth M, Sepp N. Cyclophosphamide therapy is effective for bronchiolitis obliterans occurring as a late manifestation of lupus erythematosus. Br J Dermatol. 2000;143:453-5.
11. Reilly JJ Jr. Chronic lung transplant rejection: Bronchiolitis obliterans. UpToDate 2006.
12. Matsuyama W, Yamamoto M, Machida K, Oonakahara K, Watanabe M, Higashimoto I, Osame M, Arimura K. A case of bronchiolitis obliterans syndrome successfully treated by Tiotropium bromide (in Japanese). Nihon Kokyuki Gakkai Zasshi. 2006;44:404-9.
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Pharmacological treatment: Bronchodilators. 2003, NIH pp. 67-71.